JGC
EWTX icon

J. Goldman & Co’s Edgewise Therapeutics EWTX Stock Holding History

J. Goldman & Co’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-47,200
Closed -$1.26M – 518
2024
Q3 		$1.26M Buy
+47,200
New +$939K 0.04% 267

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

J. Goldman & Co's EWTX Position: Q2 2026 in Review

J. Goldman & Co reduced its Edgewise Therapeutics (EWTX) stake by 83% in Q2 2026, selling an estimated $1.77M and leaving 10,183 shares worth $414K. The position accounts for 0.01% of the portfolio, ranked #573.

J. Goldman & Co first reported a position in EWTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $2.86M in Q4 2024. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • J. Goldman & Co held 10,183 shares of Edgewise Therapeutics worth $414K as of Q2 2026.
  • J. Goldman & Co sold 51,238 Edgewise Therapeutics shares in Q2 2026, an estimated $1.77M.
  • Edgewise Therapeutics made up 0.01% of J. Goldman & Co's portfolio in Q2 2026, its #573 holding.
  • J. Goldman & Co first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • J. Goldman & Co's Edgewise Therapeutics position peaked at $2.86M in Q4 2024.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on J. Goldman & Co's 13F filing for Q2 2026, filed 14 Aug 2026.